1stOncology™: Cancer Intelligence Service – Page 114 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Biodexa Announces Partnership with Syngene To Manufacture MTX240 GMP Clinical Trial Supplies

On April 2, 2026 Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) ("Biodexa" or "Company"), a clinical stage biopharmaceutical company developing a clinical stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers, reported that it has partnered with Syngene International Ltd (BSE: 539268, NSE: SYNGENE) ("Syngene") for the manufacture of both MTX240 active pharmaceutical ingredient and dosage form.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Commenting, Dan Palmer, Vice President, Technology at Biodexa said "We are delighted to be partnering with Syngene for the second time. Syngene manufactured tolimidone dosage form for us on time and on budget and, given the license for MTX240 from Otsuka was only signed in early February, they have once again demonstrated their responsiveness and flexibility in designing a program to manufacture GMP product within only a few weeks"

About MTX240, its Unique Mechanism of Action, Clinical Rationale and Next Steps
Molecular glue technology represents a novel approach that induces targeted protein interactions, offering a distinct mechanism of action to conventional kinase inhibitors for rare oncology indications.

Gastrointestinal Stromal Tumors ("GIST") is mostly driven by activating mutations in the KIT and/or PDGFR receptor tyrosine kinase. While tyrosine kinase inhibitors (TKIs) such as imatinib, sunitinib, and regorafenib are reported to have significantly improved outcomes for GIST patients, resistance almost always develops through secondary KIT or PDGFR mutations or activation of alternative signalling pathways. This represents a substantial clinical challenge with limited therapeutic options for patients once they have cycled through the available TKIs.

MTX240 acts as a molecular glue, bringing two intracellular proteins, PDE3a and SLFN12, specifically co-expressed by GIST cancer cells, into close proximity to form a stable complex. This interaction stabilizes SLFN12, enabling it to drive RNase-mediated apoptosis in GIST cells through a mechanism independent of KIT signalling. By triggering cell death through this alternative pathway, MTX240 is designed to overcome the resistance mechanisms that render TKI-resistant GISTs refractory to conventional kinase inhibitors. This novel mechanism may provide clinical benefit for a significant proportion of GIST patients, not only those who have developed resistance to TKIs.

Biodexa is planning to file an IND and initiate a Phase 1b/2a study towards the end of the year. The study will likely be in two parts: a dose escalation part to establish a safe and tolerable dose followed by an expansion part designed to generate an efficacy signal in TKI-resistant GIST patients.

(Press release, Biodexa Pharmaceuticals, APR 2, 2026, View Source [SID1234664164])

Dxcover Highlights Liquid Biopsy Platform Performance in Multiple Settings

On April 2, 2026 Dxcover, a global leader in AI-enabled technologies, reported the presentation of multiple studies at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting taking place in San Diego, California this month.

The company will present data as part of key sessions focused on Early Detection Approaches – specifically Stage I and II cancers, which can be treated when detected, but are elusive to other screening protocols. Matthew Baker, PhD, CEO & co-Founder of Dxcover, commented: "Cancer is detected too late because early signals are invisible to current clinical tools. The Dxcover approach analyzes the body’s earliest reactions to malignancy – a perfect complement to existing high specificity diagnostics."

Data presented at the conference represent results from studies designed to investigate the Dxcover platform’s clinical feasibility and performance capabilities:

90+% sensitivity reported consistently across stage I-IV colorectal (CRC), pancreatic, and ovarian cancers
Integration, comparative performance and considerations of CRC biomarkers and screening modalities
"It’s exciting to share our latest findings at the AACR (Free AACR Whitepaper) conference," says James Cameron, PhD, Dxcover Clinical Program Manager and co-author on each presentation. "These data demonstrate our commitment to improving patient outcomes with continued progress toward earlier cancer detection."

Dxcover AACR (Free AACR Whitepaper) presentations: #5115, #5116, #7616, #7617

(Press release, Dxcover, APR 2, 2026, View Source [SID1234664163])

Palleon Pharmaceuticals to Present on Development of HLX316/E-688 at the American Association for Cancer Research (AACR) Annual Meeting

On April 2, 2026 Palleon Pharmaceuticals, a company developing engineered enzyme therapies that remove excessive sialic acid to treat autoimmune diseases and cancer, reported upcoming presentations at the 2026 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting, taking place in San Diego from April 17 – 22. Palleon will make an oral presentation during the "New Drugs on the Horizon" series on Sunday, April 19 and will present a poster on Wednesday, April 22.

Details of Palleon’s Presentations:

American Association for Cancer Research Annual Meeting
Title: A First-in-Class Human Sialidase-Armed Anti-B7-H3 Antibody that Enhances Innate and Adaptive Antitumor Immune Responses
Abstract ID: 7158
Oral Presentation Session Date and Time: Sunday, April 19 from 3:00 PM to 4:30 PM PT
Poster Presentation Session Date and Time: Wednesday, April 22 from 9:00 AM to 12:00 PM PT
Session Category: Experimental and Molecular Therapeutics
Session Title: Overcoming Microenvironmental and Delivery Barriers in Cancer Therapy

HLX316/E-688 is a first-in-class investigational treatment developed from Palleon’s EAGLE (Enzyme-Antibody Glycan-Editing) Platform. Palleon’s HLX316/E-688 is being developed in China by Shanghai Henlius Biotech and is designed to address key mechanisms of immune evasion by enhancing the desialylation of tumor cells that express B7-H3 to help restore both innate and adaptive anti-tumor responses in the tumor microenvironment. The China National Medical Products Administration (NMPA) has cleared Henlius’ Investigational New Drug (IND) application for a Phase 1 clinical trial of HLX316/E-688 in China for the treatment of advanced or metastatic solid tumors.

The presentations will be made available on the Glycobiology Education section of Palleon Pharmaceuticals’ website.

(Press release, Palleon Pharmaceuticals, APR 2, 2026, View Source [SID1234664162])

CanWell Pharma Announces FDA Clearance of the IND for CAN016, a Dual-Payload ADC Targeting HER2, for ADC Pre-Treated Solid Tumors

On April 2, 2026 CanWell Pharma Inc. reported that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for CAN016, a HER2-targeting dual-payload ADC. The company will initiate a Phase I clinical study to evaluate CAN016 in solid tumor patients who have experienced disease progression following prior ADC therapies.

About CAN016

CAN016 is an ADC in development by CanWell Pharma Inc. for ADC pre-treated solid tumors. Developed using CanWell’s StarLinker platform, CAN016 is distinguished by its integration of two distinct MoA cytotoxic agents within a single antibody construct, leading to enhanced anti-tumor activity through complementary mechanisms. This design is expected to counter the resistance mechanisms that limit the efficacy of conventional single payload ADCs.

In preclinical studies, CAN016 effectively delivered dual cytotoxic payloads into tumor cells leading to synergistic tumor cell killing, inhibition of proliferation, and apoptosis. CAN016 has demonstrated potent anti-tumor activity in multiple CDX and PDX models, including those resistant to currently approved HER2-targeted ADC therapies.

The Phase I study will assess the safety, tolerability, and pharmacokinetics of CAN016, determine the recommended dose for subsequent clinical development, and explore preliminary anti-tumor efficacy across a range of HER2-expressing ADC pre-treated solid tumors.

(Press release, Canwell Pharma, APR 2, 2026, View Source [SID1234664161])

Caris Life Sciences Announces Launch of Caris ChromoSeq, the World’s First Whole Genome and Whole Transcriptome Tumor Profiling Assay for Myeloid Malignancies

On April 2, 2026 Caris Life Sciences (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, reported the launch of Caris ChromoSeq, a Whole Genome Sequencing (WGS) and Whole Transcriptome (WTS) assay designed to support the comprehensive clinical genomic evaluation of myeloid malignancies. The test is intended for use in acute myeloid leukemia (AML), myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN), as well as in patients with suspected myeloid malignancies characterized by unexplained cytopenia persisting for more than four months, where other potential causes have been reasonably excluded.

Myeloid malignancies are among the most genetically complex cancers, often requiring multiple tests to identify clinically relevant mutations, structural variants and chromosomal abnormalities. This fragmented approach can delay critical treatment decisions and miss detection of important genomic alterations used for diagnosis and risk stratification.

Caris ChromoSeq can replace the multiple test protocols of the myeloid diagnostic workflow, complementing the clinician’s overall clinical and pathological evaluation. Building on this foundation, the test delivers approximately 250x read depth across the genome with 40 million transcriptome reads, enabling enhanced genomic resolution from a bone marrow aspirate or peripheral blood collection. Results are synthesized into a single, easy‑to‑interpret, actionable report to support confident, timely clinical decision‑making, with an expected seven-day turnaround time.

"The Caris ChromoSeq launch provides an unprecedented amount of genomic and transcriptomic data per patient, enabling a complete diagnostic evaluation in a single test. Never before have patients and physicians had access to a technology with the depth and breadth provided by Caris ChromoSeq," said Matthew Oberley, MD, PhD, Senior Vice President, Chief Clinical Officer and Pathologist-in-Chief at Caris. "This launch reflects our commitment to delivering a single, integrated genomic solution for patients with hematological cancers that fits into real‑world clinical workflows and provides results fast enough to inform patient care."

The launch of Caris ChromoSeq underscores Caris Life Sciences’ ongoing focus on advancing precision medicine through innovative molecular profiling technologies that simplify complexity and support clinicians across the cancer care continuum.

(Press release, Caris Life Sciences, APR 2, 2026, View Source [SID1234664160])